Finance

Beta
Lists
214390:KRX
Kyongbo Pharmaceutical Co Ltd
â‚©5,350.00
+1.71%
(+90.00) 1D
Jun 10, 3:30:30 PM GMT+9  ·   KRW
All symbols
SymbolPriceChange% Change
Generating top insights for 214390...
Open
â‚©5,300
High
â‚©5,360
Low
â‚©5,150
Mkt. cap
127.90B
Avg. vol.
85.92K
Volume
35.90K
Dividend
0.93%
Quarterly dividend
â‚©12
Ex-dividend date
Dec 29, 2025
P/E ratio
381.36
52-wk high
â‚©9,300
52-wk low
â‚©4,755
EPS
â‚©14
Shares outstanding
23.91M
No. of employees
582
Open
â‚©5,300
High
â‚©5,360
Low
â‚©5,150
Mkt. cap
127.90B
Avg. vol.
85.92K
Volume
35.90K
Dividend
0.93%
Quarterly dividend
â‚©12
Ex-dividend date
Dec 29, 2025
P/E ratio
381.36
52-wk high
â‚©9,300
52-wk low
â‚©4,755
EPS
â‚©14
Shares outstanding
23.91M
No. of employees
582
News stories
From sources across the web
About Kyongbo Pharmaceutical Co Ltd
CEOKim Tae-young
Employees582
FoundedMar 31, 1987
Headquarters-
SectorPharmaceutical industry
Websitekbpharma.co.kr
Previous reportsAll values in KRW
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in KRW
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
65.31B
66.99B
71.22B
66.13B
Cost of goods sold
38.42B
42.39B
44.46B
38.69B
Cost of revenue
38.42B
42.39B
44.46B
38.69B
Research and development expenses
4.43B
4.46B
4.50B
4.92B
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
19.32B
18.88B
20.67B
20.97B
Operating expense
24.49B
24.12B
26.24B
26.73B
Total operating expenses
62.91B
66.51B
70.70B
65.41B
Operating income
2.41B
474.48M
515.50M
712.77M
Other non operating income
-3.41B
-1.10B
2.51B
-1.44B
EBT including unusual items
-1.03B
3.44B
-995.05M
-741.91M
EBT excluding unusual items
-1.03B
3.44B
-857.95M
-741.91M
Income tax expense
704.68M
412.26M
-562.40M
-212.24M
Effective tax rate
-68.56%
11.97%
56.52%
28.61%
Other operating expenses
174.39M
194.62M
276.72M
190.08M
Net income
-1.73B
3.03B
-432.65M
-529.67M
Net profit margin
-2.65%
4.53%
-0.61%
-0.80%
Earnings per share
-
-
-
-
Interest and investment income
-
-
41.30M
-
Interest expense
-
-
-4.29B
-
Net interest expenses
-
-
-4.25B
-
Depreciation and amortization charges
146.67M
377.69M
385.22M
323.46M
EBITDA
5.65B
3.86B
3.95B
4.29B
Gain or loss from assets sale
-12.00M
-6.40M
10.00K
-5.48M
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer